Hurthle Cell Carcinoma Market Size Share Growth and Trends Report 2024

Market Overview:

The global Hurthle cell carcinoma treatment market is projected to grow at a high CAGR from 2024 to 2031. Hurthle cell carcinoma accounts for about 5% of all differentiated thyroid carcinomas and is more prevalent in females. The market has experienced significant growth due to the adoption of targeted therapies such as iodine-131 in radioactive iodine treatment.

Market Dynamics:

Advancements in research and development have significantly driven market growth. Hurthle cell carcinoma is typically diagnosed through medical history, clinical, and imaging findings. New research on therapeutic targets has shown promising results. According to an article published in the Springer Journal in April 2023, Lenvatinib, a tyrosine kinase inhibitor, has been effective in treating unresectable Hurthle cell carcinoma, significantly increasing progression-free survival.

The rise in drug approvals by regulatory bodies is a key market driver. For instance, in October 2022, Innovent Biologics, Inc. announced that the National Medical Products Administration (NMPA) of China approved the New Drug Application (NDA) for selpercatinib for treating advanced or metastatic thyroid cancer with a RET gene fusion. Such approvals are expected to boost the market during the forecast period.

Hurthle cell carcinomas can cause significant complications, such as local invasion into vital structures in the neck and metastasis to lymph nodes, lungs, bone, and the brain. These complications pose treatment challenges and may hamper market growth.

Download Sample: https://www.datamintelligence.com/download-sample/hurthle-cell-carcinoma-market

Segment Analysis:

Radioactive iodine therapy accounted for approximately 38.5% of the global Hurthle cell carcinoma treatment market share. This therapy is reliable for targeting thyroid cells while minimizing exposure to other body cells. For instance, a clinical trial conducted by the Hospital of Xiamen University on July 11, 2023, evaluated the safety and tolerability of 177Lu-DOTA-EB-FAPI in patients with metastatic radioactive iodine refractory thyroid cancer.

Geographical Analysis:

North America held approximately 40.4% of the market share in 2022 and is expected to maintain its dominance due to factors such as a high prevalence of thyroid cancers, increased research and development, and technological advancements. According to the American Cancer Society, an estimated 43,670 new cases of thyroid cancer are expected in the United States in 2023, with 2,120 deaths. These statistics highlight the region's significant market potential.

To access the complete report: https://www.datamintelligence.com/research-report/hurthle-cell-carcinoma-market

Competitive Landscape:

Major global players in the Hurthle cell carcinoma treatment market include:

Bayer Healthcare Pharmaceuticals, Amgen Inc., Sanofi S.A., AstraZeneca, Novartis AG, Eli Lilly and Company, Hikma Pharmaceuticals, Pfizer Inc., Genentech Inc., Blueprint Medicines.

These companies are actively engaged in research and development to introduce innovative treatments and enhance their market presence.

Related Reports:

Follicle Stimulating Hormone Market: https://www.datamintelligence.com/research-report/follicle-stimulating-hormone-market

Sedation Therapy Market: https://www.datamintelligence.com/research-report/sedation-therapy-market

Renin-Inhibitors Market: https://www.datamintelligence.com/research-report/renin-inhibitors-market

Hepatitis B Vaccine Market: https://www.datamintelligence.com/research-report/hepatitis-b-vaccine-market

Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: DataMIntelligence

About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.